JP2005200419A - 癌治療法 - Google Patents

癌治療法 Download PDF

Info

Publication number
JP2005200419A
JP2005200419A JP2005009439A JP2005009439A JP2005200419A JP 2005200419 A JP2005200419 A JP 2005200419A JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005200419 A JP2005200419 A JP 2005200419A
Authority
JP
Japan
Prior art keywords
cancer
agonist
peroxisome proliferator
responsive receptor
troglitazone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005009439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005200419A5 (enExample
Inventor
Shuang-En Chuang
シュアン−エン チュアン
Chih-Jung Yao
チー−ジュン ヤオ
Gi-Ming Lai
ギ−ミン ライ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of JP2005200419A publication Critical patent/JP2005200419A/ja
Publication of JP2005200419A5 publication Critical patent/JP2005200419A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2005009439A 2004-01-16 2005-01-17 癌治療法 Pending JP2005200419A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53723504P 2004-01-16 2004-01-16

Publications (2)

Publication Number Publication Date
JP2005200419A true JP2005200419A (ja) 2005-07-28
JP2005200419A5 JP2005200419A5 (enExample) 2008-02-28

Family

ID=34619679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005009439A Pending JP2005200419A (ja) 2004-01-16 2005-01-17 癌治療法

Country Status (4)

Country Link
US (2) US20050209292A1 (enExample)
EP (1) EP1555021A1 (enExample)
JP (1) JP2005200419A (enExample)
TW (1) TWI297606B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529953A (ja) * 2008-08-07 2011-12-15 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療
WO2013146435A1 (ja) * 2012-03-26 2013-10-03 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤
WO2014054798A1 (ja) * 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
US8815837B2 (en) 2008-08-07 2014-08-26 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2015046388A1 (ja) 2013-09-25 2015-04-02 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨
JP2016504402A (ja) * 2013-01-14 2016-02-12 ヘルス クリニックス リミテッド 抗がん剤および使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150534B2 (en) 2012-02-28 2015-10-06 Northwestern University Prodrugs of fluorinated mevalonates to inhibit the mevalonate pathway of Streptococcus pneumoniae
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US20240058335A1 (en) * 2021-01-08 2024-02-22 Duke University Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971540A (ja) * 1995-07-03 1997-03-18 Sankyo Co Ltd 動脈硬化症予防および治療剤
JP2000513031A (ja) * 1997-06-16 2000-10-03 ファイザー・プロダクツ・インク 癌治療の為のＨＭＧ ＣｏＡレダクターゼ阻害剤との組合せに於けるファルネシルトランスフェラーゼ阻害剤
JP2001510462A (ja) * 1996-12-11 2001-07-31 ダナ・フアーバー・キヤンサー・インスチチユート 腫瘍細胞の成長を阻害するための方法および製薬学的組成物
JP2002128700A (ja) * 2000-08-16 2002-05-09 Sankyo Co Ltd 癌を予防及び治療するための医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
US6459003B1 (en) * 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
CA2415742A1 (en) * 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2003053974A1 (en) * 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971540A (ja) * 1995-07-03 1997-03-18 Sankyo Co Ltd 動脈硬化症予防および治療剤
JP2001510462A (ja) * 1996-12-11 2001-07-31 ダナ・フアーバー・キヤンサー・インスチチユート 腫瘍細胞の成長を阻害するための方法および製薬学的組成物
JP2000513031A (ja) * 1997-06-16 2000-10-03 ファイザー・プロダクツ・インク 癌治療の為のＨＭＧ ＣｏＡレダクターゼ阻害剤との組合せに於けるファルネシルトランスフェラーゼ阻害剤
JP2002128700A (ja) * 2000-08-16 2002-05-09 Sankyo Co Ltd 癌を予防及び治療するための医薬組成物

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078885B2 (en) 2008-08-07 2015-07-14 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8815837B2 (en) 2008-08-07 2014-08-26 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
JP2011529953A (ja) * 2008-08-07 2011-12-15 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療
JP2016102129A (ja) * 2012-03-26 2016-06-02 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤
US10660882B2 (en) 2012-03-26 2020-05-26 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
US20150045396A1 (en) 2012-03-26 2015-02-12 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
WO2013146435A1 (ja) * 2012-03-26 2013-10-03 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤
US9987333B2 (en) 2012-10-04 2018-06-05 Shionogi & Co., Ltd. Method for suppressing malignant tumor metastasis
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
WO2014054798A1 (ja) * 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
JP2016504402A (ja) * 2013-01-14 2016-02-12 ヘルス クリニックス リミテッド 抗がん剤および使用
WO2015046388A1 (ja) 2013-09-25 2015-04-02 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨
EP3632428A1 (en) 2013-09-25 2020-04-08 Nippon Chemiphar Co., Ltd. Zaltoprofen for use in the prophylactic or therapeutic treatment of giant cell tumors occurring in bone and soft tissue or of chondrosarcoma
US10653667B2 (en) 2013-09-25 2020-05-19 Nippon Chemiphar Co., Ltd Drug for preventing, treating or preventing metastasis of giant cell tumor that occurs in bone or soft parts, chondrosarcoma, or osteosarcoma, local injection for arterial embolization, and artificial bone
KR20220000993A (ko) 2013-09-25 2022-01-04 닛뽕 케미파 가부시키가이샤 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골

Also Published As

Publication number Publication date
TW200529813A (en) 2005-09-16
US20050209292A1 (en) 2005-09-22
US20090082406A1 (en) 2009-03-26
EP1555021A1 (en) 2005-07-20
TWI297606B (en) 2008-06-11

Similar Documents

Publication Publication Date Title
US20090082406A1 (en) Cancer Therapy
Sidera et al. HSP90 inhibitors: current development and potential in cancer therapy
JP6835472B2 (ja) 癌の処置のための組成物
JP6532878B2 (ja) 組合せ医薬
JP2020521734A (ja) 老化細胞除去化合物
JP2021512101A (ja) 肥満細胞症の治療のための併用療法
US20140336210A1 (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
BRPI0620058A2 (pt) combinação farmacêutica compreendendo compostos inibidores da ligação da proteìna smac a proteìnas inibidoras de apoptose, e um taxano, bem como uso da mesma
CN104428001A (zh) Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
JP2016510732A (ja) キノリンスルホニル誘導体及びそれらの使用
JP2021505526A (ja) 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法
JP2006070032A (ja) 抗血管形成薬剤組成物
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
JP2026515785A (ja) 微小管標的剤
Hsu et al. Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
KR20130101519A (ko) Ｈｄａｃ 억제제와 혈소판감소증 약물의 조합물
KR20080048488A (ko) Ｄｍｘａａ를 포함하는 암 치료용 조합물
WO2022247881A1 (zh) 治疗肿瘤的联合疗法
RS56699B1 (sr) Stabilizovani amorfni oblik agomelatina, postupak za njegovu izradu i farmaceutske kompozicije koje ga sadrže
TWI403509B (zh) 一種用以治療癌症之藥學組合物
US10512631B2 (en) Chalcone compounds
US20090306098A1 (en) Combination of roscovitine and a hdca inhibitor to treat proliferative diseases
KR20080044277A (ko) 유기 화합물의 조합물
WO2010061907A1 (ja) 抗癌剤

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124